Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]P16-129 PET Imaging in Alzheimer's Disease
NCT03902548Phase 1Completed
- Sponsor
- Five Eleven Pharma, Inc.
- Start
- Feb 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]P16-129 in Alzheimer's disease (AD) (2 arms), sponsored by Five Eleven Pharma, Inc. Primary endpoints: Regional brain uptake of [18F]P16-129 and [18F]florbetapir and Cumulative organ [18F]P16-129 activity for estimates of radiation absorbed dose and effective dose. Started Feb 2018; status: completed.
02
Drugs
[18F]P16-129
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03902548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902548.